Trial Profile
Phase 1 single-dose pharmacokinetic (PK) study for three separate once-daily (QD) formulations of dalfampridine in patients with Post-Stroke Walking Difficulty
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 May 2016
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Stroke complications
- Focus Pharmacokinetics
- 03 May 2016 New trial record